A first-in-human trial is the first real test of whether a drug candidate’s preclinical promise translates into human biology. Biomarkers in clinical trials can show whether a drug reaches its intended target, changes the relevant biological pathway, or produces a measurable response in people. A molecule may show strong activity in cellular assays and animal models, and its mechanism may appear convincing. But those findings do not confirm that the same effect will occur in people. In first-in-human clinical trials, biomarker data can help connect drug exposure with target engagement and biological response, alongside safety and pharmacokinetic results.
Safety remains the primary concern in first-in-human studies, but safety and pharmacokinetic data alone may leave critical questions unanswered. Did the drug engage its target? Was the administered dose biologically active? Did the expected pathway respond? Is the absence of an early clinical effect caused by insufficient exposure, unsuitable patient selection, or failure of the underlying mechanism? Biomarkers help answer these questions while there is still time to act on the findings.
Why biomarkers are important in early clinical development
The transition from preclinical research to human testing introduces uncertainty around exposure, tissue distribution, target engagement, and safety. Biomarkers provide evidence that helps assess these uncertainties and trace the relationship between dose, exposure, target engagement, biological response, and clinical outcome. A first-in-human trial may not establish this entire sequence, but evidence generated at any point along this pathway can significantly strengthen confidence in dose selection and subsequent development decisions.
Confirming target engagement and biological activity
Pharmacokinetic measurements show how much drug is present in blood or another sampled matrix. However, they do not necessarily show whether the drug has reached the relevant tissue or interacted with its intended target. Target-engagement biomarkers provide evidence that the intended pharmacological interaction has occurred. Depending on the modality and mechanism, this may be assessed through receptor occupancy, enzyme inhibition, protein phosphorylation, ligand suppression, gene-expression changes, cellular responses, or imaging-based measurements.
This distinction is important when interpreting a negative result. If adequate drug exposure and target engagement are demonstrated but no downstream response occurs, the biological hypothesis may be weak. Conversely, if target engagement cannot be demonstrated, the lack of efficacy may reflect inadequate dosing, suboptimal formulation, poor tissue distribution, insufficient assay sensitivity, or limited access to the target tissue. Without a suitable biomarker-based insight, these different failure modes can be indistinguishable.
Pharmacodynamic biomarkers show what happens biologically after treatment. They may reveal mechanisms such as suppression of a cytokine, modulation of an intracellular pathway, reduction in a disease-associated protein, or changes in an immune-cell population. When pharmacokinetic and pharmacodynamic findings are examined together, we can begin to understand the exposure-response relationship and identify when biological activity appears, whether it increases with exposure, whether target engagement reaches a plateau, and how long the effect lasts.
Syngene’s integrated translational approach
For biomarker data to be useful in a first-in-human study, the biomarker strategy must be closely aligned with the biological hypothesis established during preclinical studies and develop a meaningful correlation with clinical outcomes.. Syngene supports biomarker strategy across discovery, preclinical development, translational research, bioanalysis, and early clinical development. This integrated structure helps maintain scientific continuity as a program moves from experimental models into human studies.
Biomarker discovery and translational planning
Syngene can support the identification and evaluation of candidate biomarkers through disease models, cellular systems, molecular profiling, pharmacology studies, and clinical samples. This helps determine whether a proposed biomarker is mechanistically relevant, measurable in an appropriate sample, and likely to provide meaningful information during clinical development.
Translational Biomarker Assay Development
Syngene’s bioanalytical capabilities support the development, optimisation, transfer, qualification, and validation of assays for pharmacokinetics, pharmacodynamics, biomarkers, anti-drug antibodies, and neutralising antibodies. The fit-for-purpose approach is particularly important in first-in-human studies because analytical rigour must match the role of the assay. An exploratory biomarker and a marker used to support a dose-escalation decision do not require identical development strategies.
PK/PD and exposure-response integration
By combining bioanalysis with pharmacokinetic, pharmacodynamic, modelling, and translational capabilities, Syngene can help sponsors interpret biomarker changes in the context of drug exposure. This supports starting-dose justification, escalation decisions, schedule optimisation, identification of biologically active exposure ranges, and dose selection for later-stage studies.
Immunogenicity assessment
For biologics and other potentially immunogenic modalities, Syngene can support anti-drug antibody and neutralising-antibody assay development and analysis. Integrating these findings with exposure, target engagement, safety, and pharmacodynamic data provides a clearer understanding of whether immunogenicity is affecting the candidate’s clinical behaviour.
Continuity from preclinical to clinical studies
Changes in assays, reagents, laboratories, matrices, or data standards can make preclinical and clinical findings difficult to compare. Syngene’s integrated capabilities can reduce this fragmentation, preserve program knowledge, and allow biomarker strategies to evolve alongside the molecule.
Biomarkers in Clinical Trials: Supporting Dose-Escalation Decisions
Dose escalation should not be viewed simply as a search for the highest tolerated dose. The more relevant objective is to identify a dose range that provides adequate exposure and biological activity with an acceptable safety profile. Biomarker evidence can strengthen these decisions by demonstrating whether the mechanism is active at a relatively low dose or whether receptor occupancy or pathway modulation has reached a plateau, indicating that further escalation is unlikely to provide additional biological benefit.
Conversely, the absence of biomarker activity may justify continued dose escalation provided safety and exposure data support further investigation. However, no single biomarker result should determine dose escalation. Clinical observations, laboratory findings, pharmacokinetics, pharmacodynamics, immunogenicity, and model-based predictions must be assessed together for a more informed approach
First-in-Human Clinical Trials: Identifying the Right Patient Population
First-in-human studies increasingly enroll patients rather than healthy volunteers, particularly in oncology, rare diseases, advanced therapies, and other settings where administration to healthy individuals is inappropriate. In these trials, disease heterogeneity can make early activity difficult to interpret because patients may differ in target expression, molecular drivers, immune status, disease stage, or previous treatment.
Exploratory biomarkers can help determine whether response is associated with a particular genomic alteration, protein signature, immune phenotype, target-expression level, or other biological characteristic. At this stage, these markers may not be ready for definitive patient selection, but their early use can guide expansion cohorts, refine enrolment criteria, and inform future precision medicine strategies.
Enabling clear Go/No-Go decisions
One of the greatest risks in drug development is continuing a weak program without enough evidence. Biomarkers can support three broad decisions. A drug development program may proceed when the candidate achieves adequate exposure, engages its target, produces the expected biological response, and has a manageable safety profile. It may need modification when the mechanism appears active, but the dose, schedule, formulation, combination strategy, assay plan, or patient population requires adjustment. It may need to stop when adequate exposure is achieved without target engagement or meaningful downstream activity, or when confidence in the candidate or its therapeutic hypothesis.
The absence of a biomarker signal must still be interpreted carefully. Poor sample quality, unsuitable collection timing, biological variability, drug interference, or an insensitive assay can produce misleading results. A failed assay should not be mistaken as a failed candidate.
Why biomarker planning must begin early
Biomarker strategy should not be added after the clinical protocol has already been designed. By that stage, the most informative samples may not be available, processing conditions may be unsuitable, or the assay may not be ready before dosing begins.
Planning should start with the intended use of each biomarker. A result used for real-time dose-escalation decisions requires greater analytical and operational readiness than an exploratory marker assessed retrospectively. Teams must consider biological relevance, sample type and collection timing, assay sensitivity and dynamic range, sample stability and shipping conditions, drug and matrix interference, expected biological variability, and the speed at which results are needed.
Assay requirements should also reflect the importance of the decision being supported. Not every exploratory biomarker requires full validation, but assays used for critical clinical decisions must be sufficiently reliable and fit for purpose.
Integrating biomarkers, PK, and immunogenicity
Syngene’s bioanalytical, central and translational laboratories can work together to support clinical sample collection, testing and data interpretation. The bioanalytical laboratory measures drug concentrations and assesses pharmacological responses and immunogenicity, while the central laboratory provides clinical safety testing, specialised analyses, sample kits and logistics support. The Clinical Translational Sciences Laboratory connects biomarker findings with disease biology and clinical samples, helping investigators examine the relationship between treatment and biological response.
For example, if a pharmacodynamic response weakens during treatment, investigators can examine drug exposure and anti-drug antibody findings alongside biomarker and clinical laboratory results to investigate possible causes. Coordinating sample management and testing across these laboratories can also reduce inconsistencies in sample handling and make the resulting data easier to interpret together.
This coordinated approach gives sponsors a more complete picture of a candidate’s behaviour in humans and helps inform subsequent development decisions.
From early evidence to better decisions
Biomarkers make first-in-human trials more informative by providing evidence of target engagement, biological activity, and mechanism of action.. When planned early and interpreted alongside PK, safety, and immunogenicity data, they help teams make better go/no-go decisions before larger clinical investments are made.
